TABLE 2.

Comparison of ceCT-Based and ⁶⁸Ga-FAPI PET/CT–Based TNM Staging of 19 Patients with Primary and Recurrent/Progressive PDAC

Patient	Clinical indication	TNM stage (CT-based)	TNM stage (FAPI PET–based)	Additional finding in FAPI PET	Staging change
1	Relapse/progression	T1 N2 M1 (LYM, PUL)	T1 N0 M1 (LYM)	(Recurrent) mediastinal lymph node metastases	Up
2	Relapse/progression	T4 N0 M1 (PER)	T4 N0 M1 (PER)	None	None
3	Relapse/progression	T3 N0 M0	T3 N0 M1 (OSS)	Bone metastasis	Up
4	Relapse/progression	T4 N0 Mx	T4 N0 M1 (PER)	Peritoneal carcinosis	Up
5	Primary staging	T1 N0 M0	T1 N0 M0	None	None
6	Relapse/progression	T3 N0 M0	T3 N0 M0	None	None
7	Relapse/progression	T4 N0 Mx	T4 N0 M0	None	None
8	Primary staging	T4 N0 Mx	T4 N0 M0	None	None
9	Primary staging	T4 N0 M0	T4 N0 M0	None	None
10	Relapse/progression	T2 N0 M0	T0 N0 M0	No local recurrence (T0)	Down
11	Relapse/progression	T4 N0 M1 (LYM, HEP)	T4 N2 M1 (LYM, HEP, OSS)	Abdominal lymph node metastases, 2 more liver metastases, bone metastasis	Up
12	Primary staging	T4 N0 Mx	T4 N0 M0	None	None
13	Primary staging	T3 N0 M0	T3 N0 M0	None	None
14	Relapse/progression	T4 N2 M1 (HEP)	T4 N2 M1 (HEP, PER)	Peritoneal carcinosis	Up
15	Primary staging	T4 N2 Mx	T4 N2 M1 (PER, PLE)	Pleural carcinosis, peritoneal carcinosis, liver metastases	Up
16	Relapse/progression	T0 N2 M1 (LYM, HEP)	T0 N2 M1 (LYM, HEP, OSS)	Bone metastasis	Up
17	Relapse/progression	T2 N0 Mx	T2 N0 M1 (HEP, PUL)	Liver metastases without CT correlate, pulmonary metastasis	Up
18	Primary staging	T1 N0 Mx	T1 N0 M0	None	None
19	Relapse/progression	T4 Nx M1 (PER)	T4 N1 M1 (PER, OSS, HEP)	Lymph nodes definable from tumor conglomerate, bone metastases, liver metastases	Up

LYM = lymphatic; PUL = pulmonary; PER = peritoneal; HEP = hepatic; PLE = pleural.